• Bestatin Reveals New Layers of Jasmonate Signaling

  2026-09-25

  The study positions bestatin as a chemical-genetic probe for jasmonate signaling: it activates jasmonate-responsive genes and developmental responses, with gene induction requiring COI1-dependent signaling but not strict dependence on jasmonate biosynthesis. Screening for bestatin-resistant Arabidopsis mutants then separated defects in bestatin response from distinct changes in jasmonate sensitivity, providing a route to identify additional pathway components.

• ALC-0159: Designing Better mRNA Readouts

  2026-09-25

  ALC-0159 is a PEG-conjugated lipid excipient used in mRNA lipid nanoparticle formulations. Explore how PET reporter imaging can help distinguish delivery from antigen expression—and how to design experiments that interpret those readouts without over-attributing them to one lipid.

• Radicicol Workflows for Hsp90 Research

  2026-09-24

  Use Radicicol to probe Hsp90-linked adipogenesis, ovarian carcinoma apoptosis, and inflammatory responses—with assay controls that help separate target engagement from nonspecific toxicity. This guide turns the product’s biochemical profile into practical pilot workflows and explains how a recent periodontal stem-cell study can inform assay design without implying a shared mechanism.

• Endothelial SGK1 Mediates Salt-Induced Vascular Stiffening

  2026-09-24

  Zhang et al. identify endothelial SGK1 as a mediator of salt- and mineralocorticoid-associated vascular stiffening, combining mouse genetics with pharmacological and cellular experiments. The results connect SGK1 activity with endothelial actin polymerization and support further mechanistic research, while not establishing SGK1 inhibition as a clinical treatment.

• Separating Growth Arrest from Cancer Cell Killing

  2026-09-23

  Hannah R. Schwartz’s dissertation argues that relative viability and fractional viability capture distinct components of anticancer drug response: changes in proliferation and cell killing. Its central practical lesson is to treat these measurements as complementary rather than interchangeable, while tracking how their relationship changes over time.

• Sulfo-NHS-Biotin for EV Protein Labeling

  2026-09-23

  Sulfo-NHS-Biotin enables aqueous, amine-selective labeling of intact cells, extracellular vesicles, and purified proteins without organic-solvent handling. This guide connects practical surface-protein workflows with EV-based targeted protein degradation studies, emphasizing controls that distinguish EV capture, protein abundance, and true target depletion.

• From DNA Synthesis to NSCLC Translation

  2026-09-22

  A mechanistic and translational framework for using EdU flow cytometry to connect CDK1–APE1 biology, cell-cycle pharmacodynamics, and NSCLC therapeutic strategy.

• Partial BACE1 Inhibition and Synaptic Transmission

  2026-09-22

  Satir et al. showed that moderate BACE inhibition can reduce amyloid-β secretion by up to 50% without impairing synaptic transmission in cultured rat cortical neurons, whereas stronger inhibition reduced both amyloid-β release and neuronal signaling. The study provides a useful exposure–response framework for Alzheimer’s disease research and cautions against treating maximal BACE1 suppression as the only therapeutic objective.

• Triazole ALDH2 Activators in Myocardial Ischemia

  2026-09-21

  The 2025 ACS Medicinal Chemistry Letters study developed triazole-based activators of aldehyde dehydrogenase 2 (ALDH2) to address oxidative aldehyde damage during myocardial ischemia–reperfusion. Molecular simulation guided the discovery of Z17, which showed strong ALDH2 activation, improved water-solubility characteristics, and protective effects on cardiac function and myocardial injury markers in mice.

• From FUBP1 Mechanism to Translational qPCR

  2026-09-21

  A mechanistic guide to translating FUBP1–FUSE biology into reproducible SYBR Green qPCR workflows, with strategic guidance for validating drug-response and gene-expression hypotheses.

• Oseltamivir Acid: From Mechanism to Translation

  2026-09-20

  A mechanism-first guide to using Oseltamivir acid in influenza antiviral research, resistance studies, and exploratory oncology workflows while keeping exposure, assay design, and translational limitations in view.

• Grazoprevir hydrate: HCV Assay Workflows

  2026-09-19

  Build sensitive, genotype-aware HCV replication assays with Grazoprevir hydrate (MK-5172 hydrate), from DMSO stock preparation through orthogonal antiviral and cytotoxicity readouts. The workflow emphasizes picomolar potency, vehicle control, resistance-aware comparisons, and practical troubleshooting for reproducible research results.

• Caffeine Workflows for Cancer and Metabolic Research

  2026-09-18

  Build reproducible Caffeine experiments around fresh aqueous stocks, concentration-response modeling, and orthogonal metabolic readouts. This guide distinguishes evidence-supported cancer cell line inhibition and obesity-model findings from practical assay extensions inspired by recent ALDH2 activator research.

• BRD4 Inhibition Enhances Erastin Ferroptosis

  2026-09-18

  A 2024 Discover Oncology study shows that BRD4 inhibition broadly sensitizes multiple cell lines to erastin-induced ferroptosis. Using pharmacological inhibitors, BRD4 knockdown, ROS analysis, ferroptosis-related gene profiling, and ChIP-sequencing, the authors identify ROS accumulation and FSP1 reduction as shared mechanistic features, while also revealing cell-specific transcriptional responses.

• Shufeng Xingbi Therapy in Allergic Rhinitis Rats

  2026-09-17

  This bioRxiv preprint examines how Shufeng Xingbi Therapy affects allergic rhinitis in OVA-sensitized rats by integrating nasal pathology, Th1/Th2-associated signaling, serum mediators, and intestinal microbiota. The findings support a gut–immune association, while the preclinical design and non-peer-reviewed status require cautious interpretation before clinical or mechanistic conclusions are drawn.

8646 records 1/577 page Next 12345 下5页 Last page